Kintara Therapeutics Ownership 2024 | Who Owns Kintara Therapeutics Now?

OverviewFinancials Chart

Institutional Ownership

4.75%

Insider Ownership

0.12%

Retail Ownership

95.13%

Institutional Holders

22.00

Kintara Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
GEODE CAPITAL MANAGEMENT, LLC	1.84%	-	14,036	-98	-0.69%	51,652,000	Mar 31, 2023
STATE STREET CORP	1.41%	-	10,721	-	-	39,453,000	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	1.40%	-	10,662	10,662	100.00%	39,236,000	Mar 31, 2023
ACADIAN ASSET MANAGEMENT LLC	0.85%	0.00%	6,480	2	0.03%	22,000	Mar 31, 2023
MORGAN STANLEY	0.44%	-	3,346	-906	-21.31%	11,808,000	Mar 31, 2023
UBS GROUP AG	0.28%	-	2,139	735	52.35%	7,548,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.24%	0.00%	1,791	1,243	226.82%	6,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.13%	-	981	32	3.37%	3,448,000	Mar 31, 2023
FMR LLC	0.00%	-	29	29	100.00%	107,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	11	-	-	39,000	Mar 31, 2023
LINDBROOK CAPITAL, LLC	-	-	-	-2,135	-100.00%	-	Mar 31, 2023
NANTAHALA CAPITAL MANAGEMENT, LLC	-	-	-	-11,901	-100.00%	-	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	-	-1	-100.00%	-	Mar 31, 2023
VANGUARD GROUP INC	-	-	-	-14,831	-100.00%	-	Mar 31, 2023

Kintara Therapeutics's largest institutional shareholder is GEODE CAPITAL MANAGEMENT, LLC, holding 1.84% of the company's total share outstanding, currently valued at $51.65M. The top 10 institutional shareholders own together 6.59% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
TOWER RESEARCH CAPITAL LLC (TRC)	0.24%	0.00%	1,791	1,243	226.82%	6,000	Mar 31, 2023
ACADIAN ASSET MANAGEMENT LLC	0.85%	0.00%	6,480	2	0.03%	22,000	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	1.40%	-	10,662	10,662	100.00%	39,236,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	1.84%	-	14,036	-98	-0.69%	51,652,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.13%	-	981	32	3.37%	3,448,000	Mar 31, 2023
UBS GROUP AG	0.28%	-	2,139	735	52.35%	7,548,000	Mar 31, 2023
STATE STREET CORP	1.41%	-	10,721	-	-	39,453,000	Mar 31, 2023
MORGAN STANLEY	0.44%	-	3,346	-906	-21.31%	11,808,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	11	-	-	39,000	Mar 31, 2023
FMR LLC	0.00%	-	29	29	100.00%	107,000	Mar 31, 2023
LINDBROOK CAPITAL, LLC	-	-	-	-2,135	-100.00%	-	Mar 31, 2023
NANTAHALA CAPITAL MANAGEMENT, LLC	-	-	-	-11,901	-100.00%	-	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	-	-1	-100.00%	-	Mar 31, 2023
VANGUARD GROUP INC	-	-	-	-14,831	-100.00%	-	Mar 31, 2023

The largest Kintara Therapeutics shareholder by % of total assets is TOWER RESEARCH CAPITAL LLC (TRC). The company owns 1.79K shares of Kintara Therapeutics (KTRA), representing 0.00% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
SUSQUEHANNA INTERNATIONAL GROUP, LLP	1.40%	-	10,662	10,662	100.00%	39,236,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.24%	0.00%	1,791	1,243	226.82%	6,000	Mar 31, 2023
UBS GROUP AG	0.28%	-	2,139	735	52.35%	7,548,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.13%	-	981	32	3.37%	3,448,000	Mar 31, 2023
FMR LLC	0.00%	-	29	29	100.00%	107,000	Mar 31, 2023
ACADIAN ASSET MANAGEMENT LLC	0.85%	0.00%	6,480	2	0.03%	22,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	11	-	-	39,000	Mar 31, 2023
STATE STREET CORP	1.41%	-	10,721	-	-	39,453,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	-	-1	-100.00%	-	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	1.84%	-	14,036	-98	-0.69%	51,652,000	Mar 31, 2023
MORGAN STANLEY	0.44%	-	3,346	-906	-21.31%	11,808,000	Mar 31, 2023
LINDBROOK CAPITAL, LLC	-	-	-	-2,135	-100.00%	-	Mar 31, 2023
NANTAHALA CAPITAL MANAGEMENT, LLC	-	-	-	-11,901	-100.00%	-	Mar 31, 2023
VANGUARD GROUP INC	-	-	-	-14,831	-100.00%	-	Mar 31, 2023

As of Mar 31 2023, Kintara Therapeutics's largest institutional buyer is SUSQUEHANNA INTERNATIONAL GROUP, LLP. The company purchased 10.66K stocks of KTRA, valued at $39.24M.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
VANGUARD GROUP INC	-	-	-	-14,831	-100.00%	-	Mar 31, 2023
NANTAHALA CAPITAL MANAGEMENT, LLC	-	-	-	-11,901	-100.00%	-	Mar 31, 2023
LINDBROOK CAPITAL, LLC	-	-	-	-2,135	-100.00%	-	Mar 31, 2023
MORGAN STANLEY	0.44%	-	3,346	-906	-21.31%	11,808,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	1.84%	-	14,036	-98	-0.69%	51,652,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	-	-1	-100.00%	-	Mar 31, 2023
STATE STREET CORP	1.41%	-	10,721	-	-	39,453,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	11	-	-	39,000	Mar 31, 2023
ACADIAN ASSET MANAGEMENT LLC	0.85%	0.00%	6,480	2	0.03%	22,000	Mar 31, 2023
FMR LLC	0.00%	-	29	29	100.00%	107,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.13%	-	981	32	3.37%	3,448,000	Mar 31, 2023
UBS GROUP AG	0.28%	-	2,139	735	52.35%	7,548,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.24%	0.00%	1,791	1,243	226.82%	6,000	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	1.40%	-	10,662	10,662	100.00%	39,236,000	Mar 31, 2023

As of Mar 31 2023, Kintara Therapeutics's biggest institutional seller is VANGUARD GROUP INC. The company sold -14.83K shares of KTRA, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
SUSQUEHANNA INTERNATIONAL GROUP, LLP	1.40%	-	10,662	10,662	100.00%	39,236,000	Mar 31, 2023
FMR LLC	0.00%	-	29	29	100.00%	107,000	Mar 31, 2023

Kintara Therapeutics's largest new institutional shareholder by number of shares is SUSQUEHANNA INTERNATIONAL GROUP, LLP, purchased 10.66K shares, valued at $39.24M, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
VANGUARD GROUP INC	-	-	-	-14,831	-100.00%	-	Mar 31, 2023
NANTAHALA CAPITAL MANAGEMENT, LLC	-	-	-	-11,901	-100.00%	-	Mar 31, 2023
LINDBROOK CAPITAL, LLC	-	-	-	-2,135	-100.00%	-	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	-	-1	-100.00%	-	Mar 31, 2023

Kintara Therapeutics's largest sold out institutional shareholder by shares sold is VANGUARD GROUP INC, sold -14.83K shares, valued at -, as of undefined.

Kintara Therapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
FIDELITY COMMONWEALTH TRUST	0.07%	234,221	-	-	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	740,814	-	-	Mar 31, 2024
FIDELITY CONCORD STREET TRUST	0.00%	336,315	-	-	Feb 29, 2024
FIDELITY CONCORD STREET TRUST	0.00%	42,803	-	-	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	12,455	-12,455	-50.00%	Mar 31, 2024
iSHARES TRUST	0.00%	85,425	-	-	Mar 31, 2024
EQ ADVISORS TRUST	0.00%	5,855	-	-	Mar 31, 2024

Kintara Therapeutics's largest mutual fund holder by % of total assets is "FIDELITY COMMONWEALTH TRUST", owning 234.22K shares, compromising 0.07% of its total assets.

Kintara Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
30 Sep, 22	22	22.22%
30 Jun, 22	18	-14.29%
31 Mar, 22	21	-12.50%
31 Dec, 21	24	-7.69%
30 Sep, 21	26	4.00%
30 Jun, 21	25	19.05%
31 Mar, 21	21	40.00%
31 Dec, 20	15	36.36%
30 Sep, 20	11	-

As of 30 Sep 22, 22 institutions are holding Kintara Therapeutics's shares, representing an increase of 22.22% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
30 Sep, 22	3,476,806	-0.11%
30 Jun, 22	3,480,487	0.79%
31 Mar, 22	3,453,272	-11.80%
31 Dec, 21	3,915,272	-26.77%
30 Sep, 21	5,346,564	92.17%
30 Jun, 21	2,782,219	22.93%
31 Mar, 21	2,263,279	337.99%
31 Dec, 20	516,748	61.25%
30 Sep, 20	320,457	-

Kintara Therapeutics (KTRA) has 3.48M shares outstanding as of 30 Sep 22, down -0.11% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
30 Sep, 22	4.75%	9.30%
30 Jun, 22	7.15%	14.46%
31 Mar, 22	7.03%	10.80%
31 Dec, 21	8.07%	3.32%
30 Sep, 21	15.60%	17.27%
30 Jun, 21	9.50%	15.90%
31 Mar, 21	7.73%	178.72%
31 Dec, 20	2.08%	59.26%
30 Sep, 20	1.87%	-

As of 30 Sep 22, Kintara Therapeutics is held by 4.75% institutional shareholders, representing a 9.30% growth compared to 30 Jun 22.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
30 Sep, 22	10	25.00%
30 Jun, 22	8	60.00%
31 Mar, 22	5	-64.29%
31 Dec, 21	14	7.69%
30 Sep, 21	13	-13.33%
30 Jun, 21	15	-11.76%
31 Mar, 21	17	54.55%
31 Dec, 20	11	-
30 Sep, 20	11	-

10 institutional shareholders have increased their position in KTRA stock as of 30 Sep 22 compared to 8 in the previous quarter (a 25.00% increase).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
30 Sep, 22	4	-
30 Jun, 22	4	-
31 Mar, 22	4	300.00%
31 Dec, 21	1	-85.71%
30 Sep, 21	7	250.00%
30 Jun, 21	2	-
31 Mar, 21	-	-100.00%
31 Dec, 20	3	-
30 Sep, 20	-	-

4 institutional shareholders have reduced their position in KTRA stock as of 30 Sep 22 compared to 4 in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
30 Sep, 22	22	22.22%	3,476,806	-0.11%	4.75%	9.30%	10	25.00%	4	-
30 Jun, 22	18	-14.29%	3,480,487	0.79%	7.15%	14.46%	8	60.00%	4	-
31 Mar, 22	21	-12.50%	3,453,272	-11.80%	7.03%	10.80%	5	-64.29%	4	300.00%
31 Dec, 21	24	-7.69%	3,915,272	-26.77%	8.07%	3.32%	14	7.69%	1	-85.71%
30 Sep, 21	26	4.00%	5,346,564	92.17%	15.60%	17.27%	13	-13.33%	7	250.00%
30 Jun, 21	25	19.05%	2,782,219	22.93%	9.50%	15.90%	15	-11.76%	2	-
31 Mar, 21	21	40.00%	2,263,279	337.99%	7.73%	178.72%	17	54.55%	-	-100.00%
31 Dec, 20	15	36.36%	516,748	61.25%	2.08%	59.26%	11	-	3	-
30 Sep, 20	11	-	320,457	-	1.87%	-	11	-	-	-

Kintara Therapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Feb 17, 2022	Hoffman Robert E.	director, officer	President and CEO	P-Purchase	Buy	55,000	$0.47	$25.80K	55,000
Dec 09, 2021	Praill Anthony Scott	officer	Chief Financial Officer	P-Purchase	Buy	28,700	$0.68	$19.43K	37,186
Dec 08, 2021	Zarrabian Saiid	director, officer	Head of Strategic Partnerships	P-Purchase	Buy	38,109	$0.64	$24.30K	55,500
Dec 08, 2021	Zarrabian Saiid	director, officer	Head of Strategic Partnerships	P-Purchase	Buy	11,891	$0.59	$7.02K	17,391
Nov 24, 2021	Johnson Laura L.	director	-	P-Purchase	Buy	3,000	$0.74	$2.23K	3,000

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Feb 17, 2022	Hoffman Robert E.	director, officer	President and CEO	P-Purchase	Buy	55,000	$0.47	$25.80K	55,000
Dec 09, 2021	Praill Anthony Scott	officer	Chief Financial Officer	P-Purchase	Buy	28,700	$0.68	$19.43K	37,186
Dec 08, 2021	Zarrabian Saiid	director, officer	Head of Strategic Partnerships	P-Purchase	Buy	38,109	$0.64	$24.30K	55,500
Dec 08, 2021	Zarrabian Saiid	director, officer	Head of Strategic Partnerships	P-Purchase	Buy	11,891	$0.59	$7.02K	17,391
Nov 24, 2021	Johnson Laura L.	director	-	P-Purchase	Buy	3,000	$0.74	$2.23K	3,000

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Sep 01, 2023	Johnson Laura L.	director	-	A-Award	Buy	8,500	$4.66	$39.57K	8,500
Sep 01, 2023	FAVORITO TAMARA A	director	-	A-Award	Buy	8,500	$4.66	$39.57K	8,500
Sep 01, 2023	Hoffman Robert E.	director, officer	President, CEO and Interim CFO	A-Award	Buy	23,142	$4.66	$107.73K	23,142
Sep 01, 2023	TOTH ROBERT JOSEPH JR	director	-	A-Award	Buy	8,500	$4.66	$39.57K	8,500
Sep 01, 2023	Brown Dennis M	officer	Chief Scientific Officer	A-Award	Buy	10,175	$4.66	$47.36K	10,175
Jun 02, 2023	Hoffman Robert E.	director, officer	President, CEO, and CFO	A-Award	Buy	59,800	-	-	68,902
Jan 06, 2023	Brown Dennis M	officer	Chief Scientific Officer	W-Will	Buy	363	-	-	5,302
Aug 03, 2022	Praill Anthony Scott	officer	Chief Financial Officer	A-Award	Buy	240,087	-	-	277,273
Aug 03, 2022	Brown Dennis M	officer	Chief Scientific Officer	A-Award	Buy	240,087	-	-	246,905
Aug 03, 2022	Hoffman Robert E.	officer	President and CEO	A-Award	Buy	1,200,634	-	-	1,200,634
Jul 05, 2022	Johnson Laura L.	director		A-Award	Buy	100,000	-	-	100,000
Jul 05, 2022	TOTH ROBERT JOSEPH JR	director		A-Award	Buy	100,000	-	-	100,000
Jul 05, 2022	TOTH ROBERT JOSEPH JR	director	-	A-Award	Buy	100,000	$0.26	$25.50K	100,000
Jul 05, 2022	SEYMOUR TAMARA A	director		A-Award	Buy	100,000	-	-	100,000
Feb 17, 2022	Hoffman Robert E.	director, officer	President and CEO	P-Purchase	Buy	55,000	$0.47	$25.80K	55,000
Dec 09, 2021	Praill Anthony Scott	officer	Chief Financial Officer	P-Purchase	Buy	28,700	$0.68	$19.43K	37,186
Dec 08, 2021	Zarrabian Saiid	director, officer	Head of Strategic Partnerships	P-Purchase	Buy	38,109	$0.64	$24.30K	55,500
Dec 08, 2021	Zarrabian Saiid	director, officer	Head of Strategic Partnerships	P-Purchase	Buy	11,891	$0.59	$7.02K	17,391
Nov 24, 2021	Johnson Laura L.	director	-	P-Purchase	Buy	3,000	$0.74	$2.23K	3,000
Nov 10, 2021	HOFFMAN ROBERT	director, officer	President and CEO	A-Award	Buy	3,519,170	$0.96	$3.38M	3,519,170

The last insider buy of KTRA was made by Hoffman Robert E. on Feb 17 2022, buying 55,000 shares at $0.47 per share (worth $25.80K).

Kintara Therapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2023	5	-	-
Q2 2023	1	-	-
Q1 2023	1	-	-
Q3 2022	6	-	-
Q1 2022	1	-	-
Q4 2021	5	-	-
Q3 2021	5	-	-
Q2 2021	7	3	233.33%
Q1 2021	3	-	-
Q4 2020	3	-	-
Q3 2020	14	-	-
Q2 2020	13	1	1300.00%
Q1 2020	4	1	400.00%
Q4 2019	7	1	700.00%
Q3 2019	23	-	-
Q2 2019	5	6	83.33%
Q1 2019	5	-	-
Q4 2018	11	1	1100.00%
Q3 2018	5	-	-
Q2 2018	10	-	-

5 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Kintara Therapeutics's insiders, as of Q3 2023.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2023	-	-	-
Q2 2023	-	-	-
Q1 2023	-	-	-
Q3 2022	-	-	-
Q1 2022	1	-	-
Q4 2021	4	-	-
Q3 2021	-	-	-
Q2 2021	-	-	-
Q1 2021	-	-	-
Q4 2020	-	-	-
Q3 2020	2	-	-
Q2 2020	-	-	-
Q1 2020	-	-	-
Q4 2019	-	-	-
Q3 2019	2	-	-
Q2 2019	-	-	-
Q1 2019	-	-	-
Q4 2018	-	-	-
Q3 2018	-	-	-
Q2 2018	-	-	-

As of Q3 2023, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Kintara Therapeutics's stocks.

Kintara Therapeutics Peer Ownership

Ticker	Company
GOVX	GeoVax Labs, Inc.
DYAI	Dyadic International, Inc.
FRTX	Fresh Tracks Therapeutics, Inc.
LSTA	Lisata Therapeutics, Inc.
SABS	SAB Biotherapeutics, Inc.
SCPH	scPharmaceuticals Inc.
TOVX	Theriva Biologics, Inc.
MCRB	Seres Therapeutics, Inc.
FWBI	Entero Therapeutics, Inc.
BOLT	Bolt Biotherapeutics, Inc.
VCNX	Vaccinex, Inc.
KA	Kineta, Inc.
ONCY	Oncolytics Biotech Inc.
DMAC	DiaMedica Therapeutics Inc.
SLRX	Salarius Pharmaceuticals, Inc.
MIST	Milestone Pharmaceuticals Inc.
LIFE	aTyr Pharma, Inc.
CLRB	Cellectar Biosciences, Inc.
FBRX	Forte Biosciences, Inc.
LBPH	Longboard Pharmaceuticals, Inc.
LUMO	Lumos Pharma, Inc.

KTRA Ownership FAQ

Who Owns Kintara Therapeutics?

Kintara Therapeutics is owned by institutional shareholders (4.75%), insiders (0.12%), and public (95.13%). The largest institutional shareholder of Kintara Therapeutics is GEODE CAPITAL MANAGEMENT, LLC (1.84% of total shares) and the top mutual fund owner is FIDELITY COMMONWEALTH TRUST (0.07% of total shares).

Who are the major institutional shareholders of Kintara Therapeutics?

Kintara Therapeutics's major institutional shareholders are GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, ACADIAN ASSET MANAGEMENT LLC, and MORGAN STANLEY. The top five shareholders own together 5.94% of the company's share outstanding.

How many Kintara Therapeutics shareholders are there?

As of Sep 2022, there are 22 institutional shareholders of Kintara Therapeutics.

What percentage of Kintara Therapeutics is owned by GEODE CAPITAL MANAGEMENT, LLC?

GEODE CAPITAL MANAGEMENT, LLC owns 14.04K shares of Kintara Therapeutics, representing 1.84% of the company's total shares outstanding, valued at $51.65M (as of Mar 2023).

What percentage of Kintara Therapeutics is owned by STATE STREET CORP?

As of Mar 2023, STATE STREET CORP holds 10.72K shares of Kintara Therapeutics (KTRA), compromising 1.41% of the company, valued at $39.45M.

What percentage of Kintara Therapeutics is owned by SUSQUEHANNA INTERNATIONAL GROUP, LLP?

SUSQUEHANNA INTERNATIONAL GROUP, LLP is the third largest holder of Kintara Therapeutics. The company owns 10.66K of the company's shares outstanding (worth $39.24M).